This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. In particular, we cannot be certain that we will ever achieve sustained profitability, that the rate of reimbursement for PTNS treatments will be adequate to justify the cost of our product, that other Medicare carriers or private payers will provide coverage for this treatment or that existing carriers and payers will not change their coverage decisions, that the rate of adoption of our products by new customers will continue, or that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.
For Further Information:
Brett Reynolds, SVP and CFO
Leigh Salvo/ (Investors)/Janine McCargo (Business Media)
UROPLASTY, INC. AND SUBSIDIARIES
CONDENSED Consolidated Statements of Operations
(Unaudited)Three Months EndedSix Months EndedSeptember 30September 302013201220132012Net sales
$5,976,875$5,709,840$11,817,716$11,286,963Cost of goods sold
5,235,0334,934,87710,327,8279,756,413Operating expensesGeneral and administrative
|SOURCE Uroplasty, Inc.|
Copyright©2012 PR Newswire.
All rights reserved